Sentences with phrase «brentuximab vedotin»

A phase II trial of brentuximab vedotin (anti-CD30 antibody - drug conjugate) in combination with chemotherapy and radiation therapy for younger patients with advanced Hodgkin lymphoma (NCT01920932).

Five - year survival data published online in Blood, the Journal of the American Society of Hematology (ASH), suggest that the targeted therapy brentuximab vedotin may have cured some Hodgkin lymphoma patients whose disease has persisted despite receiving previous therapies.

The FDA has approved brentuximab vedotin (Adcetris) to treat adults with previously untreated stage III or IV cHL, in combination with chemotherapy.

Those treated with brentuximab vedotin plus AVD were 23 % less likely to experience progression, death, or initiation of new therapy compared with those receiving ABVD.

The targeted drug brentuximab vedotin (Adcetris ®)-- a monoclonal antibody linked to a chemotherapy drug — is approved to treat Hodgkin lymphoma in patients whose disease has failed to respond to other treatment and, as of August 2015, to prevent relapse following a stem cell transplant.

This multinational Phase II study examines brentuximab vedotin (BV) in patients with Hodgkin lymphoma who relapsed after stem cell transplant.

«It is critical to note that nine of the complete response patients have been in remission for over five years after receiving only brentuximab vedotin,» said Dr. Chen, «The fact that these patients are doing so well, even five years out, provides a new perspective for prognosis.»

The FDA granted accelerated approval to nivolumab (Opdivo), an anti-PD-1 checkpoint inhibitor, for patients with classical Hodgkin lymphoma (cHL) whose disease has relapsed or progressed after stem cell transplantation and the targeted antibody brentuximab vedotin (Adcetris).

The approval was based on a clinical trial comparing brentuximab vedotin plus conmbination chemotherapy (Adriamycin [doxorubicin], vinblastine and dacarbazine, or AVD) vs a chemotherapy - only regimen commonly used to treat cHL (AVD plus bleomycin, also known as ABVD).

Recent FDA approval of front - line brentuximab vedotin with chemotherapy in patients with stage III / IV Hodgkin lymphoma offers the first new treatment for this disease in over 40 years.

These observations led her and her colleagues to test whether drugs that spur the immune system to attack cancer cells, such as checkpoint inhibitors like nivolumab, would work well with the targeted chemotherapy agent brentuximab vedotin.

Herrera's latest work builds upon phase 1 study results that he presented at the 2016 ASH meeting, measuring the safety of brentuximab vedotin — an antibody - based treatment that targets delivery of chemotherapy only to Hodgkin lymphoma cells — combined with nivolumab, which works by blocking something called the PD - 1 immune checkpoint pathway that tumors often hijack to evade the immune system.

The research team evaluated the combination of the biologic therapy brentuximab vedotin (Adcetris), a monoclonal antibody - drug conjugate, with the chemotherapy drug gemcitabine (Gemzar) in 42 pediatric and young - adult patients with Hodgkin lymphoma, the most common cancer in young people ages 15 to 29.

The US Food and Drug Administration (FDA) has approved brentuximab vedotin (Adcetris) to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL), in combination with chemotherapy.

A combination of complementary immunotherapy drugs brentuximab vedotin (Adcetris ®) and nivolumab (Opdivo ®) destroyed most cancer cells in 64 percent of patients with recurrent Hodgkin lymphoma, according to the results of an early - phase clinical trial led by Catherine M. Diefenbach, MD, assistant professor of medicine and director of the Clinical Lymphoma Program.

The researchers report that these two therapies together represent a highly active combination for refractory or relapsed Hodgkin lymphoma, with a complete response rate exceeding that seen with standard therapy or following administration of either brentuximab vedotin or gemcitabine alone.

Moreover, 18 % of the patients on the brentuximab vedotin — plus - AVD arm experienced disease progression, death, or began new therapy, compared with 22 % of the patients on the ABVD arm.

The first of these antibody - drug combinations, Adcetris (brentuximab vedotin), was approved by the FDA in 2011 to treat lymphoma.

Tags: ASH, Alex Herrera, Blood, Hodgkin lymphoma, PD - 1, brentuximab vedotin, hodgkin lymphoma, immunotherapy, nivolumab